{"result": "(\"entity\"<|>ADENOMA HIPOFISARIO<|>EVENT<|>Adenoma hipofisario is a type of tumor in the pituitary gland that can produce ACTH, leading to Cushing's syndrome.)\n##\n(\"entity\"<|>RMN<|>EVENT<|>RMN (Resonancia Magnética Nuclear) is an imaging technique used to detect pituitary adenomas in patients suspected of having Cushing's syndrome.)\n##\n(\"entity\"<|>TAC<|>EVENT<|>TAC (Tomografía Axial Computarizada) is an imaging technique that may be used to search for tumors but is less sensitive than RMN for detecting pituitary adenomas.)\n##\n(\"entity\"<|>CATETERISMO DE SENOS PETROSOS<|>EVENT<|>Cateterismo de senos petrosos is a procedure used to demonstrate the hypersecretion of ACTH from the pituitary gland.)\n##\n(\"relationship\"<|>CUSHING'S SYNDROME<|>ADENOMA HIPOFISARIO<|>Cushing's syndrome can be caused by an adenoma hipofisario that produces excess ACTH<|>8)\n##\n(\"relationship\"<|>RMN<|>ADENOMA HIPOFISARIO<|>RMN is the preferred imaging technique for detecting adenomas hipofisarios<|>7)\n##\n(\"relationship\"<|>TAC<|>ADENOMA HIPOFISARIO<|>TAC is less effective than RMN in detecting adenomas hipofisarios<|>4)\n##\n(\"relationship\"<|>CATETERISMO DE SENOS PETROSOS<|>CUSHING'S SYNDROME<|>Cateterismo de senos petrosos is performed to confirm the source of ACTH hypersecretion in Cushing's syndrome<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: -periférico de ACTH.\n             Referencias:\n             • Nieman LK. Establishing the cause of Cushing´s syndrome. En: Lacroix A, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc.\n               https://www.uptodate.com (acceso 29 de abril de 2019).\n\n\n\n48                                                                                                                                                                                                                                                                     49\n---\n                                                                                                                                                                                                                              HIPÓFISIS                        1\n\n\n\n    39  Una paciente ha sido intervenida de un adenoma hipofisario productor de ACTH,                                                 40  Un paciente presenta unos resultados de laboratorio que le inducen a pensar en\n        pero no se ha curado. Unos meses después de la intervención acude a su consulta                                                   una enfermedad de Cushing, pero en la RMN no se aprecia lesión tumoral. ¿Qué\n        francamente hipercortisólica. Usted decide tratarla con un fármaco que actúe                                                      prueba solicitaría?\n        bloqueando a nivel suprarrenal. ¿Cuál de los siguientes no lo hace?                                                               A. TAC de cuerpo entero.\n        A. Ketoconazol.                                                                                                                   B. RMN de cuerpo entero.\n        B. Metirapona.                                                                                                                    C. Cateterismo de senos petrosos.\n        C. Pasireótida.                                                                                                                   D.  PET.\n        D.  Todos lo hacen.\n                                                                                                                                          COMENTARIO\n        COMENTARIO                                                                                                                        Si las pruebas de laboratorio indican que la causa del síndrome de Cushing de un paciente\n        Dentro del tratamiento médico del síndrome de Cushing disponemos de distintos grupos                                              es   una enfermedad de Cushing, es              decir, un adenoma hipofisario           productor de ACTH,         la\n        farmacológicos:                                                                                                                   prueba de imagen indicada sería una centrada en la hipófisis. En concreto, la RMN hipofisa-\n        1.  Inhibidores de la esteroidogénesis adrenal: ketoconazol, metirapona, etomidato intrave-                                       ria presenta mejor sensibilidad que la TAC para detectar adenomas hipofisarios.\n            noso, osilodrostat (LCI699).                                                                                                  Sin embargo, hasta en el 50% de los casos la RMN no es capaz de detector tumor. Si esto\n        2.  Adrenolíticos: mitotano.                                                                                                      ocurre o si aparece una lesión hipofisaria menor de 6 mm (que podría ser un tumor no fun-\n        3.  Fármacos que actúan directamente sobre la secreción de ACTH hipofisaria: cabergolina,                                         cionante), lo recomendable es realizar un cateterismo de senos petrosos, para demostrar\n            pasireótida.                                                                                                                  la hipersecreción de ACTH hipofisaria, documentando la existencia de un gradiente petro-\n        4.  Antagonistas de los receptores de glucocorticoides: mifepristona.                                                             so-periférico de ACTH (respuesta C correcta).\n        El ketoconazol inhibe el primer paso en la biosíntesis del cortisol y en menor medida la conversión                               No tendría utilidad solicitar una TAC o una RMN de cuerpo entero, en busca de tumores con\n        de 11-desoxicortisol. También inhibe la desmolasa C17-20, disminuyendo la producción de andros-                                   producción ectópica de ACTH, si las pruebas de laboratorio sugerían adenoma hipofisario\n        tenodiona y testosterona.                                                                                                         (enfermedad de Cushing) (respuestas A y B falsas).\n        La metirapona es también un inhibidor de la esteroidogénesis adrenal, pero a diferencia del                                       Tampoco la PET ha demostrado utilidad en este contexto, puesto que detecta lesiones con\n        ketoconazol bloquea la 11-β-hidroxilasa, es decir, el paso final en la biosíntesis del cortisol.                                  gran actividad metabólica, actividad proliferativa alta y habitualmente pobremente dife-\n        Como consecuencia de la disminución de cortisol y el aumento subsidiario de ACTH que se                                           renciadas. Sin embargo, su sensibilidad es mucho menor en tumores de crecimiento lento\n        produce, se asocia a un aumento de andrógenos adrenales, que pueden causar hirsutismo en                                          (como los adenomas hipofisarios) (respuesta D falsa).\n        mujeres.                                                                                                                          Referencias:\n        La pasireótida no es inhibidor de la esteroidogénesis adrenal, sino un análogo de la soma-                                        • Nieman LK. Establishing the cause of Cushing´s syndrome. En: Lacroix A, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc.\n                                                                                                                                            https://www.uptodate.com (acceso 29 de abril de 2019).\n        tostatina. Por tanto, ejercerá su acción a nivel hipofisario, uniéndose a los receptores de so-\n        matostatina de las células corticotropas (sobre todo por su afinidad al subtipo 5 del recep-\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ACTH<|>EVENT<|>ACTH is a hormone produced by the pituitary gland that stimulates the adrenal glands to produce cortisol.)\n##\n(\"entity\"<|>NIEMAN LK<|>PERSON<|>Nieman LK is a medical professional who authored a reference on establishing the cause of Cushing's syndrome.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a clinical decision support resource that provides evidence-based information for healthcare professionals.)\n##\n(\"entity\"<|>CUSHING'S SYNDROME<|>EVENT<|>Cushing's syndrome is a condition caused by excessive cortisol production, often due to a pituitary adenoma producing ACTH.)\n##\n(\"entity\"<|>KETOCONAZOL<|>ORGANIZATION<|>Ketoconazole is a medication used to inhibit adrenal steroidogenesis in the treatment of Cushing's syndrome.)\n##\n(\"entity\"<|>METIRAPONA<|>ORGANIZATION<|>Metirapone is a drug that inhibits adrenal steroidogenesis and is used in the treatment of Cushing's syndrome.)\n##\n(\"entity\"<|>PASIREOTIDE<|>ORGANIZATION<|>Pasireotide is a medication that acts on the pituitary gland to reduce ACTH secretion.)\n##\n(\"entity\"<|>MIFEPRISTONE<|>ORGANIZATION<|>Mifepristone is an antagonist of glucocorticoid receptors used in the treatment of Cushing's syndrome.)\n##\n(\"entity\"<|>MITOTANE<|>ORGANIZATION<|>Mitotane is an adrenolytic drug used in the treatment of Cushing's syndrome.)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Alhamia Prison is a facility mentioned in the context of Cushing's syndrome treatment, though not directly related to the medical context.)\n##\n(\"relationship\"<|>NIEMAN LK<|>UPTODATE INC<|>Nieman LK authored a reference published by UpToDate Inc. regarding Cushing's syndrome<|>7)\n##\n(\"relationship\"<|>CUSHING'S SYNDROME<|>ACTH<|>Cushing's syndrome is caused by excessive levels of ACTH leading to increased cortisol production<|>8)\n##\n(\"relationship\"<|>KETOCONAZOL<|>CUSHING'S SYNDROME<|>Ketoconazole is used to treat Cushing's syndrome by inhibiting cortisol production<|>9)\n##\n(\"relationship\"<|>METIRAPONA<|>CUSHING'S SYNDROME<|>Metirapone is used to treat Cushing's syndrome by blocking cortisol synthesis<|>9)\n##\n(\"relationship\"<|>PASIREOTIDE<|>CUSHING'S SYNDROME<|>Pasireotide is used to treat Cushing's syndrome by reducing ACTH secretion<|>9)\n##\n(\"relationship\"<|>MIFEPRISTONE<|>CUSHING'S SYNDROME<|>Mifepristone is used in the treatment of Cushing's syndrome by blocking glucocorticoid receptors<|>9)\n##\n(\"relationship\"<|>MITOTANE<|>CUSHING'S SYNDROME<|>Mitotane is used in the treatment of Cushing's syndrome as an adrenolytic agent<|>9)\n<|COMPLETE|>"}]}